ZA959714B - Methods of using GDNF as a neuroprotective agent. - Google Patents

Methods of using GDNF as a neuroprotective agent.

Info

Publication number
ZA959714B
ZA959714B ZA9509714A ZA959714A ZA959714B ZA 959714 B ZA959714 B ZA 959714B ZA 9509714 A ZA9509714 A ZA 9509714A ZA 959714 A ZA959714 A ZA 959714A ZA 959714 B ZA959714 B ZA 959714B
Authority
ZA
South Africa
Prior art keywords
gdnf
methods
neuroprotective agent
present
glial
Prior art date
Application number
ZA9509714A
Other languages
English (en)
Inventor
David Martin
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of ZA959714B publication Critical patent/ZA959714B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9509714A 1994-11-15 1995-11-15 Methods of using GDNF as a neuroprotective agent. ZA959714B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15

Publications (1)

Publication Number Publication Date
ZA959714B true ZA959714B (en) 1997-10-15

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9509714A ZA959714B (en) 1994-11-15 1995-11-15 Methods of using GDNF as a neuroprotective agent.

Country Status (13)

Country Link
US (1) US5733875A (xx)
EP (1) EP0792160B1 (xx)
JP (1) JPH10508839A (xx)
AT (1) ATE205088T1 (xx)
AU (1) AU691349B2 (xx)
CA (1) CA2204911C (xx)
DE (1) DE69522578T2 (xx)
DK (1) DK0792160T3 (xx)
ES (1) ES2159647T3 (xx)
IL (1) IL115966A (xx)
PT (1) PT792160E (xx)
WO (1) WO1996014861A1 (xx)
ZA (1) ZA959714B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
TR199901734T2 (xx) * 1996-11-15 2000-01-21 Genentech, Inc. N�rotrofinlerin ar�t�lmas�.
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
PT1223966E (pt) * 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
PL2019683T5 (pl) 2006-04-25 2022-12-05 The Regents Of The University Of California Podawanie czynników wzrostu do leczenia zaburzeń OUN
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
EP3973979A1 (en) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
US5733875A (en) 1998-03-31
DE69522578T2 (de) 2002-07-11
AU691349B2 (en) 1998-05-14
WO1996014861A1 (en) 1996-05-23
EP0792160B1 (en) 2001-09-05
DE69522578D1 (de) 2001-10-11
IL115966A0 (en) 1996-01-31
IL115966A (en) 1999-11-30
ES2159647T3 (es) 2001-10-16
AU3752895A (en) 1996-06-06
DK0792160T3 (da) 2001-11-19
EP0792160A1 (en) 1997-09-03
ATE205088T1 (de) 2001-09-15
CA2204911A1 (en) 1996-05-23
CA2204911C (en) 2002-07-23
PT792160E (pt) 2002-02-28
JPH10508839A (ja) 1998-09-02

Similar Documents

Publication Publication Date Title
IL115966A0 (en) Methods of using gdnf as a neuroprotective agent
EP1674107B8 (en) Use of daptomycin
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
PL316080A1 (en) Pharmaceutic composition for sublingual or intrabuccal administration
EP0830369A4 (en) NOR-PREGNANE FOR INDUCING HYPOTHALAMIC EFFECTS
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
GB9212308D0 (en) Therapeutic compositions
AP9300561A0 (en) Antibiotic compounds.
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
MX9603819A (es) Tratamiento de tinnitus empleando agentes neuroprotectores.